A top Bayer AG executive said on Tuesday the German drugmaking and crop science company saw no need to adjust its 2026 forecasts because of tariffs on imported pharmaceuticals announced by the U.S. government last week.
Bayer US head says tariffs will not affect its 2026 forecasts
